Sectors
Capricor’s Deramiocel Voted Down 9-3 by FDA Advisory Panel
Nine advisory committee members looked at the same trial data Capricor called a win and voted against it. The 9-3 result on July 29 didn’t kill Capricor’s Duchenne muscular dystrophy program, but it added a real question mark to a therapy the company insists already cleared its bar. INmune Bio spent the same stretch doing…
SunPower’s Q2 Revenue Falls 23% on Self-Imposed Quality Holds
SunPower held back $15.3 million of already-signed, already-financed jobs from its own second quarter, on purpose, over blurry photos and missing utility bills. The company reported the results anyway on July 28. Revenue came in at $56.0 million, down 23% from the prior quarter, and the stock kept sliding toward $0.31, a level that makes…
Strategy’s $8.22B Loss and Coinbase’s Record Market Share
Strategy and Coinbase reported second-quarter earnings within hours of each other on July 30. Strategy’s loss ran into the billions, almost entirely a paper markdown on bitcoin it has no plans to sell. Coinbase’s loss was smaller and came with a record trading-volume market share attached. Both stocks fell anyway. Strategy Posts an $8.22 Billion…
America’s Antimony Push Gets a Pilot Plant. One Junior Is Already Finding More
The U.S. Army and Idaho National Laboratory opened a modular pilot plant in Idaho Falls built to process antimony, a mineral used in ammunition, batteries, and flame retardants that the United States currently gets almost entirely from China and Russia. A day earlier, a small New Brunswick company reported another round of high-grade antimony assays…
FinWise Bancorp Q2 Profit Falls 22% After Tallied Technologies Buy
A bitcoin miner born out of one of crypto’s ugliest bankruptcies just staged the biggest direct listing Nasdaq has seen in five years. Two days later, a small Utah bank holding company reported its profit fell by more than a fifth, undercut in part by the very acquisition it made ten days earlier to bring…
Nextech3D.ai Signs Definitive Agreement to Acquire Remaining ARway Shares
Nextech3D.ai spent the week finalizing terms to buy the 60% of ARway it doesn’t already own, a company that logged its first profitable quarter less than a year ago. Alset AI Ventures spent the week paying someone $5,000 a month to trade its own stock. Both are AI companies listed on Canadian exchanges. Only one…
Graphene Manufacturing Group Lands Blackwoods Distribution Deal as Two Nasdaq Financings Send Stocks in Opposite Directions
Blackwoods has stocked industrial supplies for Australian mines and factories since 1878. This month it added a liquid graphene lubricant to that catalog. Elsewhere, a $50 million financing priced above a stock’s own market value sent one Nasdaq micro-cap tumbling, while a much smaller facility sent another soaring in the same week. GMG Lands Blackwoods…
FDA Panel Votes Down Capricor’s Deramiocel 9-3 for Duchenne Cardiomyopathy
Nine advisory committee members voted against Capricor’s Duchenne muscular dystrophy therapy on Tuesday. Three voted for it. The FDA’s own briefing document had called the primary evidence unconvincing before a single panelist spoke, and a nearly identical scene is playing out for a different company on the same regulatory stage today. Altimmune, meanwhile, needed no…
QumulusAI Signs $71.9 Million AI Deal as Argo Corporation Closes $10 Million Raise and Nextech3D.ai Moves to Reacquire ARway
QumulusAI went public two weeks ago. It has already signed four separate GPU supply agreements worth more than $140 million combined, the latest landing Tuesday at $71.9 million on its own. A transit-tech company priced its newest institutional raise below where it priced its last two, and called it a strategic investment anyway. Nextech3D.ai, a…










